Form 4: Spyre Therapeutics CFO Trades Shares Under 10b5-1 Plan

Spyre Therapeutics' Chief Financial Officer, Scott L. Burrows, executed a series of stock transactions under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE), reported transactions involving the company's common stock.
• On July 1, 2026, Burrows acquired 7,500 shares of common stock at a price of $14.50 per share, totaling $108,750.
• Also on July 1, 2026, Burrows disposed of 5,775 shares at a weighted average price of $87.55, and an additional 1,725 shares at a weighted average price of $88.37.
• Following these transactions, Burrows beneficially owns 97,994 shares of common stock.
• The acquisition of 7,500 shares was made pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
• The disposal of shares occurred under the same Rule 10b5-1 plan.
• Burrows also holds stock options to purchase 404,857 shares, with a portion vested and exercisable.
• Additionally, Burrows holds 67,476 restricted stock units (RSUs) that vest over the next two years.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the CFO is selling shares, it's under a pre-established 10b5-1 plan, which is a standard compliance mechanism. The acquisition of shares at a lower price point under the same plan could be seen as a positive signal, but the sale of a larger quantity at a higher price tempers overall sentiment.

Positives

• The acquisition of 7,500 shares at $14.50 indicates a potential belief in the stock's value at that price point, possibly related to the Rule 10b5-1 plan's execution.
• The existence of a Rule 10b5-1 plan suggests pre-planned, systematic trading activity, which can reduce concerns about insider trading.
• Burrows continues to hold a significant number of shares (97,994) and stock options, indicating continued investment in the company.

Negatives

• The disposal of a substantial number of shares (7,500 shares) by the CFO, even under a 10b5-1 plan, could be perceived negatively by the market.
• The weighted average sale prices ($87.55 and $88.37) are significantly higher than the acquisition price ($14.50), indicating a substantial profit realized on the disposed shares.

Risks

• The disposal of shares by a key executive, even under a pre-arranged plan, might signal a lack of confidence in near-term price appreciation or a need for personal liquidity.
• The effectiveness and continued relevance of the Rule 10b5-1 plan in the current market conditions are subject to interpretation.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a CFO is common practice to diversify holdings or manage personal finances while adhering to insider trading regulations. The significant difference between the acquisition price of the newly acquired shares and the sale prices of disposed shares suggests a profitable period for the company or a successful execution of the plan over time.

Stakeholder Impact

• Shareholders: May interpret the CFO's sale of shares, even under a 10b5-1 plan, as a potential signal, though the plan's existence mitigates direct insider trading concerns.
• Employees: The CFO's continued stock ownership and option holdings may be seen as a sign of commitment.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• The reporting person may be required to provide further details on specific sale prices upon request from the SEC or security holders.
• Continued monitoring of Scott L. Burrows' beneficial ownership and any future transactions.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Trading, Rule 10b5-1, Stock Options, Restricted Stock Units, Scott L. Burrows, Chief Financial Officer, Beneficial Ownership, Securities Exchange Act